These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37960731)

  • 81. Increased PD-L1 Expression in Acquired Cisplatin-Resistant Lung Cancer Cells via Mir-181a.
    Chen Y; Song W; Gao Y; Dong X; Ji X
    Tohoku J Exp Med; 2022 May; 257(1):33-43. PubMed ID: 35354691
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.
    Kim DH; Kim H; Choi YJ; Kim SY; Lee JE; Sung KJ; Sung YH; Pack CG; Jung MK; Han B; Kim K; Kim WS; Nam SJ; Choi CM; Yun M; Lee JC; Rho JK
    Exp Mol Med; 2019 Aug; 51(8):1-13. PubMed ID: 31399559
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Long non-coding RNA Opa interacting protein 5-antisense RNA 1 binds to micorRNA-34a to upregulate oncogenic PD-L1 in non-small cell lung cancer.
    Qiao X; Zhao F
    Bioengineered; 2022 Apr; 13(4):9264-9273. PubMed ID: 35411833
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
    Bassanelli M; Sioletic S; Martini M; Giacinti S; Viterbo A; Staddon A; Liberati F; Ceribelli A
    Anticancer Res; 2018 Jul; 38(7):3789-3796. PubMed ID: 29970498
    [TBL] [Abstract][Full Text] [Related]  

  • 85. MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3.
    Liu W; Liu R; Yuan R; Wang X
    Mol Biotechnol; 2021 Dec; 63(12):1268-1279. PubMed ID: 34386930
    [TBL] [Abstract][Full Text] [Related]  

  • 86. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.
    He Y; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Yu H; Zhou C; Hirsch FR
    Med Sci Monit; 2017 Mar; 23():1208-1216. PubMed ID: 28275222
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity.
    Guo J; Qu H; Shan T; Chen Y; Chen Y; Xia J
    Mol Cells; 2018 Jul; 41(7):653-664. PubMed ID: 29936792
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells.
    Sp N; Kang DY; Lee JM; Jang KJ
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576006
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Phase I Trial of Intratumoral Injection of
    Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
    Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
    [No Abstract]   [Full Text] [Related]  

  • 90. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC.
    Xia Y; Wang WC; Shen WH; Xu K; Hu YY; Han GH; Liu YB
    Chem Biol Interact; 2021 Nov; 349():109652. PubMed ID: 34520751
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients.
    Fujimoto D; Uehara K; Sato Y; Sakanoue I; Ito M; Teraoka S; Nagata K; Nakagawa A; Kosaka Y; Otsuka K; Imai Y; Hamakawa H; Takahashi Y; Kokubo M; Tomii K
    Sci Rep; 2017 Sep; 7(1):11373. PubMed ID: 28900290
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
    Shirasawa M; Yoshida T; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Watanabe SI; Ohe Y; Motoi N
    Eur J Cancer; 2020 Nov; 140():28-36. PubMed ID: 33039811
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Desmoplasia in non-small cell lung carcinomas is associated with low programmed death-ligand 1 expression and the absence of tumor-infiltrating lymphocytes.
    Tancoš V; Plank L; Farkašová A; Grendár M; Mazuráková A; Huťka Z; Kviatkovská Z
    Neoplasma; 2023 Oct; 70(5):697-705. PubMed ID: 38053375
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
    Zhou C; Che G; Zheng X; Qiu J; Xie Z; Cong Y; Pei X; Zhang H; Sun H; Ma H
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Exosome-transmitted S100A4 induces immunosuppression and non-small cell lung cancer development by activating STAT3.
    Wu X; Zhang H; Jiang G; Peng M; Li C; Lu J; Jiang S; Yang X; Jiang Y
    Clin Exp Immunol; 2022 Dec; 210(3):309-320. PubMed ID: 36370151
    [TBL] [Abstract][Full Text] [Related]  

  • 96. NEDD4L suppresses PD-L1 expression and enhances anti-tumor immune response in A549 cells.
    Zhong B; Zheng J; Wen H; Liao X; Chen X; Rao Y; Yuan P
    Genes Genomics; 2022 Sep; 44(9):1071-1079. PubMed ID: 35353342
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
    Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
    Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
    [No Abstract]   [Full Text] [Related]  

  • 99. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.
    Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H
    Front Immunol; 2023; 14():1178193. PubMed ID: 37492578
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.
    Wahid M; Pratoomthai B; Egbuniwe IU; Evans HR; Babaei-Jadidi R; Amartey JO; Erdelyi V; Yacqub-Usman K; Jackson AM; Morris JC; Patel PM; Bates DO
    Cancer Immunol Immunother; 2023 Dec; 72(12):4001-4014. PubMed ID: 37973660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.